

**Supplementary information Table S1: Cytotoxicity of SARS-CoV-2 M<sup>pro</sup> inhibitors on various cell lines<sup>a</sup> and the counter screening against influenza virus.**

	GC-376 (64)	Boceprevir (28)	MG-132 (43)	Calpain inhibitor II (61)	Calpain inhibitor XII (62)
MDCK	>100	>100	0.34 ± 0.02	>100	60.36 ± 2.28
Vero	>100	>100	0.45 ± 0.02	>100	>100
HCT-8	>100	>100	0.47 ± 0.02	>100	73.29 ± 11.80
A549	>100	>100	10.71 ± 3.50	>100	>100
Caco-2	>100	>100	<0.15	>100	82.02 ± 0.37
BEAS2B	>100	>100	0.14 ± 0.03	>100	78.91 ± 13.70
A/California/07/2009 (H1N1) antiviral activity <sup>b</sup> (μM)	> 20	> 20	N.T.	> 20	> 20

<sup>a</sup>Cytotoxicity was evaluated by measuring CC<sub>50</sub> values (50% cytotoxic concentration) with CPE assay described in the method section. CC<sub>50</sub> = mean ± S.E. of 3 independent experiments. <sup>b</sup>Antiviral activity against influenza virus was tested in plaque assay.